Hypoxia-Inducible factor 1-alpha stabilizers in the treatment of inflammatory bowel diseases: Oxygen as a novel IBD therapy?

S Bhat, F Rieder - Journal of Crohn's and Colitis, 2022 - academic.oup.com
S Bhat, F Rieder
Journal of Crohn's and Colitis, 2022academic.oup.com
Despite the significant advances in the medical armamentarium for inflammatory bowel
diseases [IBD], current treatment options have notable limitations. Durable remission rates
remain low, loss of response is common, administration routes are largely parenteral for
novel biologics, and medication safety remains a concern. This explains an ongoing unmet
need for safe medications with novel mechanisms of action that are administered orally. In
line with these criteria, hypoxia-inducible factor [HIF]-1α stabilizers, acting via inhibition of …
Abstract
Despite the significant advances in the medical armamentarium for inflammatory bowel diseases [IBD], current treatment options have notable limitations. Durable remission rates remain low, loss of response is common, administration routes are largely parenteral for novel biologics, and medication safety remains a concern. This explains an ongoing unmet need for safe medications with novel mechanisms of action that are administered orally. In line with these criteria, hypoxia-inducible factor [HIF]-1α stabilizers, acting via inhibition of prolyl hydroxylase enzymes, are emerging as an innovative therapeutic strategy. We herein review the mechanism of action and available clinical data for HIF-1α stabilizers and their potential place in the future IBD treatment algorithm.
Oxford University Press